Literature DB >> 3708581

Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake.

J W Darnowski, R E Handschumacher.   

Abstract

Pools of free uridine, ranging from 7.3 to 38.0 nmol/g wet weight, have been detected in a variety of freeze-clamped murine tissues. These concentrations average 10-fold greater than that detected in plasma. The kinetics of these pools after an i.v. tracer dose of [3H]uridine suggest that the initial rapid disappearance of [3H]uridine from plasma (t1/2 = 2 min) reflects distribution into tissues as well as catabolism by the liver. Subsequently, the tissue uridine pools turn over with half-lives of 13 to 18 h. Analyses of the activity of the proximal enzymes in uridine metabolism (uridine phosphorylase and uridine kinase) suggest that the phosphorylase correlates with the size of tissue uridine pools. Further evidence for this is seen in the sustained 5- to 15-fold increase in both tissue and plasma uridine concentrations after treatment with benzylacyclouridine, a potent uridine phosphorylase inhibitor. In contrast, a nonphysiological dose of exogenous uridine (250 mg/kg) briefly increases the plasma concentration of uridine to over 1 mM but it returns to below 10 microM within 1 h. Under these conditions as well, tissue concentrations of uridine increase 5- to 10-fold in most tissues, 20-fold in spleen, and 70-fold in kidney. High cellular concentrations of free uridine relative to medium are also observed in dispersed murine splenocytes. Furthermore, splenocytes incubated in 5 microM [3H]uridine achieved a 2-fold higher intracellular concentration of [3H]uridine in less than 1 min independent of phosphorylation. Thymidine was not concentrated in this system nor did nitrobenzylthioinosine inhibit [3H]uridine uptake. These findings suggest that in normal tissues and explanted cells, pools of uridine are sustained by a concentrative transport mechanism and constitute a previously unrecognized reservoir of pyrimidine nucleosides in tissues.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708581

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.

Authors:  Deliang Cao; Amy Ziemba; James McCabe; Ruilan Yan; Laxiang Wan; Bradford Kim; Michael Gach; Stuart Flynn; Giuseppe Pizzorno
Journal:  Mol Cancer Ther       Date:  2011-09-27       Impact factor: 6.261

2.  Microarray analysis of newly synthesized RNA in cells and animals.

Authors:  M Kenzelmann; S Maertens; M Hergenhahn; S Kueffer; A Hotz-Wagenblatt; L Li; S Wang; C Ittrich; T Lemberger; R Arribas; S Jonnakuty; M C Hollstein; W Schmid; N Gretz; H J Gröne; G Schütz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-03       Impact factor: 11.205

3.  Induction of the differentiation of HL-60 cells by phorbol 12-myristate 13-acetate activates a Na(+)-dependent uridine-transport system. Involvement of protein kinase C.

Authors:  C W Lee; J A Sokoloski; A C Sartorelli; R E Handschumacher
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

4.  Reduction of equilibrative nitrobenzylthioinosine-sensitive nucleoside transporter in tamoxifen-treated MCF-7 cells: an oestrogen-reversible phenomenon.

Authors:  L B Goh; C W Lee
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

5.  Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells.

Authors:  J Cai; C W Lee
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

Review 6.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

7.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.

Authors:  G J Peters; C J van Groeningen; E J Laurensse; J Lankelma; A Leyva; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Enhancement of pertussis-toxin-sensitive Na(+)-dependent uridine transporter activity in HL-60 granulocytes by N-formylmethionyl-leucyl-phenylalanine.

Authors:  L B Goh; J A Sokoloski; A C Sartorelli; C W Lee
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

10.  Inhibition by pertussis toxin of the activation of Na(+)-dependent uridine transport in dimethyl-sulphoxide-induced HL-60 leukaemia cells.

Authors:  J A Sokoloski; A C Sartorelli; R E Handschumacher; C W Lee
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.